Benign Prostatic Hyperplasia

被引：183
作者：
Langan, Robert C. [1 ,2 ]
机构：
[1] Sacred Heart Campus, St Lukes Family Med Residency, 450 Chew St,Suite 101, Allentown, PA 18102 USA
[2] Temple Univ, Sch Med, Dept Family & Community Med, Philadelphia, PA 19122 USA
来源：
PRIMARY CARE | 2019年 / 46卷 / 02期
关键词：
Benign prostatic hyperplasia; Lower urinary tract symptoms; Alpha-adrenergic blockers; 5-alpha reductase inhibitors; Transurethral resection of the prostate; URINARY-TRACT SYMPTOMS; ADVERSE EVENTS; URETHRAL LIFT; FINASTERIDE; MEN; ASSOCIATION; RISK; PROGRESSION; TAMSULOSIN; MANAGEMENT;
D O I：
10.1016/j.pop.2019.02.003
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
Benign prostatic hyperplasia (BPH) is a common condition in aging men that is frequently associated with troublesome lower urinary tract symptoms (LUTS). The American Urologic Association Symptom Index is a validated, self-administered tool that is used to diagnose LUTS, guide initial treatment, and assess treatment response. Watchful waiting is an option for men with mild symptoms. Pharmacologic treatment includes alpha-adrenergic blockers and 5-alpha reductase inhibitors. There is no evidence to support the use of herbal supplements in the treatment of LUTS. Surgical therapy is effective and indicated for men with complications from BPH or who fail medical therapy.
引用
收藏
页码：223 / +
页数：11
相关论文
共 44 条
[1]   Tadalafil for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: Pathophysiology and Mechanism(s) of Action [J].
Andersson, Karl-Erik ;
de Groat, William C. ;
McVary, Kevin T. ;
Lue, Tom F. ;
Maggi, Mario ;
Roehrborn, Claus G. ;
Wyndaele, Jean Jacques ;
Melby, Thomas ;
Viktrup, Lars .
NEUROUROLOGY AND URODYNAMICS, 2011, 30 (03) :292-301
[2]   Antimuscarinics for treatment of overactive bladder [J].
Andersson, KE .
LANCET NEUROLOGY, 2004, 3 (01) :46-53
[3]   THE AMERICAN-UROLOGICAL-ASSOCIATION SYMPTOM INDEX FOR BENIGN PROSTATIC HYPERPLASIA [J].
BARRY, MJ ;
FOWLER, FJ ;
OLEARY, MP ;
BRUSKEWITZ, RC ;
HOLTGREWE, HL ;
MEBUST, WK ;
COCKETT, ATK ;
BLAIVAS, JG ;
WEIN, AJ .
JOURNAL OF UROLOGY, 1992, 148 (05) :1549-1557
[4]   BENIGN PROSTATIC HYPERPLASIA SPECIFIC HEALTH-STATUS MEASURES IN CLINICAL RESEARCH - HOW MUCH CHANGE IN THE AMERICAN-UROLOGICAL-ASSOCIATION SYMPTOM INDEX AND THE BENIGN PROSTATIC HYPERPLASIA IMPACT INDEX IS PERCEPTIBLE TO PATIENTS [J].
BARRY, MJ ;
WILLIFORD, WO ;
CHANG, YC ;
MACHI, M ;
JONES, KM ;
WALKERCORKERY, E ;
LEPOR, H .
JOURNAL OF UROLOGY, 1995, 154 (05) :1770-1774
[5]   Dihydrotestosterone and the concept of 5α-reductase inhibition in human benign prostatic hyperplasia [J].
Bartsch, G ;
Rittmaster, RS ;
Klocker, H .
EUROPEAN UROLOGY, 2000, 37 (04) :367-380
[6]   Association Between Tamsulosin and Serious Ophthalmic Adverse Events in Older Men Following Cataract Surgery [J].
Bell, Chaim M. ;
Hatch, Wendy V. ;
Fischer, Hadas D. ;
Cernat, Geta ;
Paterson, J. Michael ;
Gruneir, Andrea ;
Gill, Sudeep S. ;
Bronskill, Susan E. ;
Anderson, Geoffrey M. ;
Rochon, Paula A. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2009, 301 (19) :1991-1996
[7]   Serum prostate-specific antigen as a predictor of prostate volume in the community: The krimpen study [J].
Bohnen, Arthur M. ;
Groeneveld, Frans P. ;
Bosch, J. L. H. Ruud .
EUROPEAN UROLOGY, 2007, 51 (06) :1645-1653
[8]   Intraoperative floppy iris syndrome associated with tamsulosin [J].
Chang, DF ;
Campbell, JR .
JOURNAL OF CATARACT AND REFRACTIVE SURGERY, 2005, 31 (04) :664-673
[9]   Initiation of nonselective alpha1-antagonist therapy and occurrence of hypotension-related adverse events among men with benign prostatic hyperplasia:: A retrospective cohort study [J].
Chrischilles, E ;
Rubenstein, L ;
Chao, J ;
Kreder, KJ ;
Gilden, D ;
Shah, H .
CLINICAL THERAPEUTICS, 2001, 23 (05) :727-743
[10]   A meta-analysis on the efficacy and tolerability of α1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction [J].
Djavan, B ;
Marberger, M .
EUROPEAN UROLOGY, 1999, 36 (01) :1-12
12345